Jung-Min Lee

18PUBLICATIONS
125CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 24, 2026
DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers.

Tzu-Ting Huang, Jayakumar R Nair, Courtney Bowen

|Mar 05, 2026
Ovarian cancer.

Clare L Scott, Susana Banerjee, Florence Joly

|Dec 08, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

Takeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz

|Nov 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Jung-Min Lee, Junya Tabata, Tzu-Ting Huang

|Nov 07, 2025
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.

Margaret R Pruitt, Kellsye P Fabian, Jung-Min Lee

|Jul 16, 2025
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions.

Hayley L Rein, Yashpal Rawal, Anna L Palovcak-Lightbourn

Pageof 3

Frequent Collaborators

5 joint publications

Tzu-Ting Huang

4 joint publications

Jayakumar R Nair

3 joint publications

Nahoko Sato

3 joint publications

Elizabeth M Swisher